In summary, we identified and validated that DAB2IP CpG1 methylation is a practical prognostic biomarker for ccRCC that can add significant prognostic value to established clinicopathologic parameters. The gene discussed is DAB2IP; the disease is nonpapillary renal cell carcinoma.